News

Sagimet Biosciences Advances Acne Treatments with Positive Results

Sagimet Biosciences Advances Acne Treatments with Positive Results

Sagimet Biosciences Reports Second Quarter Financial Results

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company focused on innovative therapeutics, has made notable strides in developing its drugs targeting dysfunctional metabolic and fibrotic pathways. Recently, they released their financial results for the quarter ending June 30, 2025, and shared compelling corporate updates regarding their product pipeline.

Successful Phase 3 Clinical Trials for Denifanstat

In a significant development, Sagimet's license partner, Ascletis Bioscience Co. Ltd., announced that denifanstat achieved all primary and secondary endpoints in a Phase 3 trial for moderate to severe acne in China. The trial enrolled 480 participants who were randomized to receive either denifanstat or a placebo. The results were overwhelmingly positive, demonstrating denifanstat's efficacy and tolerability as a treatment option for acne.

Key Findings from the Phase 3 Trial

The trial highlighted several key endpoints that were successfully met:

  • 33.2% of patients on denifanstat reached treatment success defined by clear skin or almost clear skin compared to only 14.6% of those on placebo.
  • Denifanstat showed a 57.4% reduction in total acne lesions compared to a 35.4% reduction for placebo.
  • Moreover, there was a 63.5% decrease in inflammatory lesions against a 43.2% decrease in the placebo group.
  • The secondary endpoint related to non-inflammatory lesions also showed promising results with a 51.9% reduction versus 28.9% for placebo.

Following 12 weeks of daily administration, adverse events were comparable between both groups, further confirming its safety profile.

Market Implications

The implications of these findings are significant, especially considering acne affects more than 50 million individuals in the U.S. annually. This potential advancement in acne treatment options could address a long-standing gap in innovation for this widespread condition.

New Clinical Trials on the Horizon

Following the success with denifanstat, Sagimet moved quickly to expand its treatment options. The company has initiated the first-in-human Phase 1 clinical trial for another FASN inhibitor, TVB-3567, aimed at acne management in the U.S. This trial will assess the safety and pharmacokinetics of the drug in healthy participants and those with acne.

Combination Therapy Development

Looking towards the future, Sagimet is also planning a Phase 1 trial to evaluate a combination therapy of denifanstat and resmetirom. If successful, this could pioneer a new combination treatment strategy for managing metabolic dysfunction associated steatohepatitis (MASH).

Financial Overview for Q2 2025

Sagimet reported cash, cash equivalents, and marketable securities totaling $135.5 million as of June 30, 2025. Their research and development expenditures were approximately $7.2 million for the quarter, reflecting an increase from the previous year, underscoring their commitment to advancing their clinical programs.

Comparative Financial Data

General and administrative expenses reached $4.7 million, up slightly from $4.3 million last year. Despite these expenses, the overall investment in research indicates a strong focus on growth and innovation.

Outlook and Future Milestones

The company is positioned to maintain momentum, with upcoming milestones expected in the second half of 2025 for the continuation of their clinical trials. Sagimet aims to advance the Phase 2 program for acne treatments in 2026, which hinges on the outcomes of their ongoing Phase 1 trials.

About Sagimet Biosciences

Sagimet is dedicated to developing novel fatty acid synthase inhibitors that target metabolic and fibrotic diseases. Their lead candidate, denifanstat, has gained Breakthrough Therapy designation from the FDA for treating MASH due to promising Phase 2b trial results.

Frequently Asked Questions

What is the purpose of Sagimet Biosciences?

Sagimet focuses on developing therapies to treat metabolic and fibrotic diseases through innovative drug candidates.

What did the Phase 3 trial for denifanstat achieve?

The trial met all primary and secondary endpoints, showcasing its efficacy in treating moderate to severe acne.

How does Sagimet’s financial health look?

As of June 30, 2025, Sagimet has a strong cash position of $135.5 million, allowing for continued investment in clinical trials.

What are the company’s next steps following Phase 1 trials?

Sagimet aims to further its combination therapy research as well as continue to develop the Phase 2 program for acne treatment.

Who is the target market for the treatments developed by Sagimet?

Sagimet targets individuals suffering from acne and metabolic dysfunction, particularly MASH, seeking effective treatment options.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 94

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
Oman’s Dhofar II Wind Deal Clears Financing Hurdle

Updated Category News Views 111

Dhofar’s next wind farm has crossed the line that matters: financial close. That is less glamorous than turbines spinning against an Omani skyline, but it is the point where a project stops being an attractive deck and becomes a real contractual obligation. Sembcorp Utilities, alongside OQ Alternative Energy through Naseem Dhofar SAOC, has brought the 125-megawatt...

Continue Reading
Trip.Best Expands Global Travel Discovery Footprint

Updated Category News Views 123

Sydney just became the map pin for a fairly serious travel-content land grab. Trip.Best, Trip.com Group's ranking brand, has rolled out its 2027 Annual Rankings with coverage of all seven continents for the first time. This is not an earnings release, and nobody should pretend a hotel list magically turns into revenue by lunchtime. Still, the jump from 85 to 98 annual...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 105

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Surgery Partners Deal Faces Fresh Price Scrutiny Ahead

Updated Category News Views 66

A $23.50 cash offer can look wonderfully tidy until somebody asks how the number was built. That is where Surgery Partners shareholders find themselves after Halper Sadeh LLC said it is investigating the proposed sale of Surgery Partners, Inc. to HealthSpan Partners. The firm is examining whether the company’s board obtained a fair price, ran a conflict-free process,...

Continue Reading
Franklin County Trees Raise Funds and Honor Veterans

Updated Category News Views 23

Holiday charity works best when it gives people something tangible to gather around, and Franklin County has found a pretty sturdy version of that formula. Its eighth annual Festival of Trees opens at 4 p.m. Saturday, November 21, at the Franklin County 11/30 Visitors Center in downtown Chambersburg, carrying the theme A Salute To Veterans. More than 80 decorated trees...

Continue Reading
Bybit Adds ANT, but Trading Access Has Real Fine Print

Updated Category News Views 50

Anthropic shares have landed on Bybit Stocks, and the headline is simple enough: eligible customers can trade ANT after the company’s public listing. But this is one of those announcements where the plumbing deserves as much attention as the shiny new ticker. A platform can make access feel effortless right up until a jurisdiction rule, a verification hurdle, or a...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 65

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 47

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading

Top 5 Most Recently Viewed Articles

Deere & Co's Future Amid Repair Debates and Financial Insights

Updated Category News Views 81

Barclays Reconfirms Target for Deere & Co Barclays recently reaffirmed its Overweight rating on Deere & Co (NYSE: DE) and maintained a $400 price target, amidst an ongoing dialogue surrounding the right to repair. This discussion has re-emerged in the spotlight, temporarily impacting Deere's share price before it regained ground. The analyst noted that this issue has been...

Continue Reading
Inventor Offers Hospital Sign to Prevent Infections

Updated Category News Views 38

A Fresh Take on Infection Control Some days you stumble across an idea that just clicks—like the latest gadget for hospitals. Forget complex systems or high-tech cameras; this is about a simple sign that screams 'stop!' before you walk into trouble. It’s designed to safeguard hospital staff by alerting them to take precautions before entering rooms with infectious...

Continue Reading
JPMorgan Adjusts NOV Stock Outlook Amidst Market Challenges

Updated Category News Views 64

JPMorgan Adjusts NOV Stock Outlook Recently, JPMorgan made changes to its financial outlook for NOV Inc. (NYSE: NOV), a key player in the energy equipment and services sector. The investment firm lowered its price target from $23 to $22 but maintained an Overweight rating on the stock. This adjustment was driven by expectations of a slowdown in North American operations...

Continue Reading
Madrigal Pharmaceuticals Expands Workforce with Incentive Awards

Updated Category News Views 234

Madrigal Pharmaceuticals Strengthens Workforce with New Grants Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a leading biopharmaceutical company dedicated to innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH), has recently taken a significant step to bolster its team. The company announced granting equity inducement awards to 76 new...

Continue Reading
Pomerantz Investigates Investor Claims Against Abacus Global Management

Updated Category News Views 272

Pomerantz Law Firm's Investigation into Abacus Global Management In recent news, the Pomerantz Law Firm has embarked on an investigation regarding Abacus Global Management, Inc. (NASDAQ: ABL). This investigation revolves around potential securities fraud and other unlawful business practices committed by the company and some of its executive members. For investors...

Continue Reading